Begin main content

Call for Feedback: Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation

January 22, 2019
A document related to the project entitled Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation is now available for feedback from all interested stakeholders. Project Call for Feedback Feedback Due By Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation 2019-01-22 2019-02-05 Consultation Document Product Type Submit ...

New at CADTH - January 2019

January 9, 2019
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

Call for Patient Input and Clinical Experts: halobetasol propionate and tazarotene

January 7, 2019
CADTH has received the following notice(s) of pending drug submission(s).  Brand name TBC Generic name halobetasol propionate and tazarotene Manufacturer Bausch Health, Canada Inc. Indication(s) Psoriasis, moderate to severe plaque Project Number SR0600-000 Call for patient input 2019-01-07 Patient input deadline 2019-02-26 Submit patient input ...

Call for Patient Input: Xultophy

January 2, 2019
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website. Xultophy Brand name Generic name Manufacturer ...

Pharmaceutical Reviews Update 4

December 13, 2018
See Pharmaceutical Reviews Update – Issue 4 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: an upcoming webinar on the CADTH/pCODR clinician input and feedback process an update on the transition of the Cancer Drug Implementation Advisory Committee work a reminder about pre-submissio...